ORYPKI
Live / Applied — Fourth extension granted (statement of use) (as of 07 Aug 2025)
What this means for you
Not registered yet, but its 27 Apr 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97910219
- Mark type
- Stylized text
- Filed
- 27 Apr 2023
- Published for opposition
- 25 Jul 2023
- Attorney of record
- Alexandra Kochian
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical products for the prevention and treatment of immunological diseases, pharmaceutical preparations for the treatment of central nervous system diseases and disorders, pharmaceutical preparations for the treatment of Amyotrophic Lateral Sclerosis, Multiple Sclerosis, and Alzheimer's
Owner
- Genzyme Corporation, Cambridge, MA, US
- Genzyme Corporation, Cambridge, MA, US
Prosecution history
- 10 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 08 Aug 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 07 Aug 2025 — SOU EXTENSION 4 GRANTED
- 07 Aug 2025 — SOU EXTENSION 4 FILED
- 07 Aug 2025 — SOU TEAS EXTENSION RECEIVED
- 26 Jun 2025 — TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
- 26 Jun 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 26 Jun 2025 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 26 Jun 2025 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 04 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 24 Jan 2025 — SOU EXTENSION 3 GRANTED
- 23 Jan 2025 — SOU EXTENSION 3 FILED
- 23 Jan 2025 — SOU TEAS EXTENSION RECEIVED
- 03 Jul 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 03 Jul 2024 — SOU EXTENSION 2 GRANTED